View ValuationInnovotech 将来の成長Future 基準チェック /06現在、 Innovotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長17.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: CA$648.1k (down 44% from 1Q 2025). Net loss: CA$399.6k (down CA$464.8k from profit in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Apr 07Innovotech Inc., Annual General Meeting, Jun 16, 2026Innovotech Inc., Annual General Meeting, Jun 16, 2026. Location: alberta, edmonton CanadaReported Earnings • Apr 04Full year 2025 earnings releasedFull year 2025 results: Revenue: CA$4.53m (up 107% from FY 2024). Net income: CA$94.4k (down 58% from FY 2024). Profit margin: 2.1% (down from 10% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.New Risk • Mar 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.8% per year over the past 5 years. High level of non-cash earnings (68% accrual ratio). Market cap is less than US$10m (CA$8.32m market cap, or US$6.06m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$4.5m revenue, or US$3.2m).お知らせ • Feb 07Innovotech Inc. Announces Executive Changes, Effective February 1, 2026Innovotech Inc. announced the appointments of Jodi McDonald as Chief Operating Officer and Rod Szarka as Chief Commercial Officer (CCO) of the Company, each effective February 1, 2026. Ms. McDonald was previously President of Keystone Labs Inc. (Keystone), which was recently amalgamated with Innovotech Labs Corporation (Labs). Both Keystone and Labs were wholly owned subsidiaries of Innovotech Inc., and their amalgamation into a single entity as Innovotech Labs Corporation was previously announced on January 2, 2026, having been completed on January 1st, 2026. Ms. McDonald has led Keystone for more than 20 years, building and scaling a regulated laboratory business with a strong focus on quality, client service and team development. She holds a Bachelor of Science in Medical Laboratory Science from the University of Alberta. The company announced the appointment of Rod Szarka as Chief Commercial Officer. Mr. Szarka was previously Vice President of Marketing and Business Development at Keystone, where he was responsible for building client relationships and expanding service offerings. In his new role as CCO of Innovotech, Mr. Szarka will oversee revenue generation across the Company, including responsibility for business development, client relationships and the buildout of a dedicated sales and client service team for all Innovotech business lines.out of a dedicated sales and client service team for all Innovotech business lines. Rod has a strong track record of translating technical capabilities into clear value for clients, added Dr. Milne. His experience growing Keystones client base and his understanding of the needs of regulated life sciences companies make him the right leader to build out Innovotechs commercial engine. With Jodi focused on operations and Rod focused on growth, we are strengthening the leadership team needed to scale our life sciences business.New Risk • Dec 04New major risk - Revenue and earnings growthEarnings have declined by 9.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.8% per year over the past 5 years. High level of non-cash earnings (68% accrual ratio). Market cap is less than US$10m (CA$10.5m market cap, or US$7.54m). Minor Risk Revenue is less than US$5m (CA$4.5m revenue, or US$3.2m).お知らせ • Nov 21Innovotech Inc. announced that it has received CAD 0.2 million in fundingOn November 20, 2025, Innovotech Inc. closed the transaction. No finders' fees were paid with respect to the offering. The company announced that it has closed on the convertible debenture for an aggregate principal amount of CAD 200,000. The debenture and all accrued and unpaid interest shall mature on October 15, 2030, being 60 months from the date of issuance of the debenture. The principal amount of the debenture may, at the option of the debenture holder, be converted, in whole or in part, at any time before the maturity date into common shares of company at a price of CAD 0.25 per common share.Recent Insider Transactions Derivative • Sep 28Independent Director exercised options to buy CA$118k worth of stock.On the 24th of September, Shong-Tak Tam exercised options to buy 589k shares at a strike price of around CA$0.17, costing a total of CA$100k. This transaction amounted to 22% of their direct individual holding at the time of the trade. Since December 2024, Shong-Tak's direct individual holding has increased from 1.85m shares to 2.72m. Company insiders have collectively bought CA$430k more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Aug 21Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.003 loss in 2Q 2024)Second quarter 2025 results: CA$0.005 loss per share (further deteriorated from CA$0.003 loss in 2Q 2024). Revenue: CA$984.3k (up 147% from 2Q 2024). Net loss: CA$239.5k (loss widened 109% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 09+ 1 more updateAn undisclosed buyer acquired an undisclosed stake in CanBiocin Inc. from Innovotech Inc. (TSXV:IOT) for CAD 0.55 million.An undisclosed buyer acquired an undisclosed stake in CanBiocin Inc. from Innovotech Inc. (TSXV:IOT) for CAD 0.55 million on July 1, 2025. As part of the consideration, Innovotech Inc. (TSX-V: IOT) has received approximately CAD 0.550562 million following the sale of its 0.12 million shares in CanBiocin. An undisclosed buyer completed the acquisition of an undisclosed stake in CanBiocin Inc. from Innovotech Inc. (TSXV:IOT) for CAD 0.55 million on July 1, 2025.Recent Insider Transactions • May 19Independent Director recently bought CA$92k worth of stockOn the 14th of May, Shong-Tak Tam bought around 434k shares on-market at roughly CA$0.21 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$279k more in shares than they have sold in the last 12 months.Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: CA$1.16m (up 269% from 1Q 2024). Net income: CA$65.2k (up CA$167.4k from 1Q 2024). Profit margin: 5.6% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.お知らせ • May 06Innovotech Inc., Annual General Meeting, Jul 08, 2025Innovotech Inc., Annual General Meeting, Jul 08, 2025.Reported Earnings • Apr 16Full year 2024 earnings releasedFull year 2024 results: Revenue: CA$2.19m (up 86% from FY 2023). Net income: CA$224.7k (up CA$382.3k from FY 2023). Profit margin: 10% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 20Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: CA$436.1k (up 150% from 3Q 2023). Net loss: CA$21.3k (loss narrowed 82% from 3Q 2023).New Risk • Nov 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m (CA$1.2m revenue, or US$878k). Market cap is less than US$10m (CA$6.13m market cap, or US$4.38m). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding).お知らせ • Nov 06+ 1 more updateInnovotech Inc. (TSXV:IOT) completed the acquisition of Keystone Labs Inc.Innovotech Inc. (TSXV:IOT) signed a letter of intent to acquire Keystone Labs Inc. for CAD 0.52 million on September 10, 2024. As part of consideration, CAD 0.3 million is paid towards common equity of Keystone Labs Inc. The consideration for the acquisition of the Keystone equity will be in an amount of up to $600,000 by the issuance to the Keystone shareholders the equivalent of CAD 300,000 of Innovotech shares from treasury at the price of CAD 0.13 per common share. These acquisition Shares will be subject to an escrow agreement whereby the Acquisition Shares shall be released over a two-year period, which is designed to retain Ms. McDonald in her leadership capacity. Additionally, the Company will issue a performance-based cash incentive plan valued at up to a further CAD 300,000 over a three-year period contingent on achieving revenue growth and positive net income targets. The LOI will be followed by a definitive agreement which will be subject to customary conditions, due diligence and representations, warranties and covenants. As of October 21, 2024, Innovotech Inc. signed a definitive purchase agreement to acquire Keystone Labs Inc. for CAD 0.51 million. Innovotech will acquire 100% of Keystone’s shares on a debt-free basis for up to CAD 516,698. This includes issuing CAD 216,698 in Innovotech shares at CAD 0.13 per common share. A performance-based cash incentive plan of up to CAD 300,000 is also offered, contingent on revenue growth and positive net income over three years. On October 30, 2024 conditional acceptance by the TSX Venture Exchange. Innovotech anticipated closing date in October of 2024. The closing date is expected to be in the latter part of November 2024, subject to the acceptance of the TSX Venture Exchange (TSXV). Innovotech Inc. (TSXV:IOT) completed the acquisition of Keystone Labs Inc. on November 5, 2024.お知らせ • Sep 12+ 1 more updateInnovotech Inc. (TSXV:IOT) signed a letter of intent to acquire Keystone Labs Inc. for CAD 0.9 million.Innovotech Inc. (TSXV:IOT) signed a letter of intent to acquire Keystone Labs Inc. for CAD 0.9 million on September 10, 2024. A cash consideration of CAD 0.3 million will be paid by Innovotech Inc. As part of consideration, CAD 0.3 million is paid towards common equity of Keystone Labs Inc. Innovotech anticipated closing date in October of 2024. The consideration for the acquisition of the Keystone equity will be in an amount of up to $600,000 by the issuance to the Keystone shareholders the equivalent of CAD 300,000 of Innovotech shares from treasury at the price of CAD 0.13 per common share. These Acquisition Shares will be subject to an escrow agreement whereby the Acquisition Shares shall be released over a two-year period, which is designed to retain Ms. McDonald in her leadership capacity. Additionally, the Company will issue a performance-based cash incentive plan valued at up to a further CAD 300,000 over a three-year period contingent on achieving revenue growth and positive net income targets. The Company is also pleased to announce a non-brokered private placement of up to CAD 1,000,000. The LOI will be followed by a definitive agreement which will be subject to customary conditions, due diligence and representations, warranties and covenants. The Company intends to use CAD 300,000 to clear the existing shareholder loan balances at Keystone and a further CAD 100,000 for equipment purchases as required in the short to medium term to augment Keystone’s existing laboratory equipment. The balance of the proceeds from the private placement will be used for unallocated working capital and for conducting further business development of the combined business operations.Reported Earnings • Aug 22Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: CA$398.6k (down 3.0% from 2Q 2023). Net loss: CA$114.8k (down 258% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 115 percentage points per year, which is a significant difference in performance.Recent Insider Transactions Derivative • Aug 18President exercised options to buy CA$5.6k worth of stock.On the 15th of August, Craig Milne exercised options to buy 40k shares at a strike price of around CA$3,200, costing a total of CA$128m. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2023, Craig's direct individual holding has increased from 160.00k shares to 294.00k. Company insiders have collectively bought CA$128m more than they sold, via options and on-market transactions, in the last 12 months.お知らせ • May 16Innovotech Inc., Annual General Meeting, Jul 16, 2024Innovotech Inc., Annual General Meeting, Jul 16, 2024.Reported Earnings • Apr 25Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.004 loss in FY 2022)Full year 2023 results: CA$0.004 loss per share (in line with FY 2022). Revenue: CA$1.18m (up 5.0% from FY 2022). Net loss: CA$157.6k (loss widened 15% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • Dec 13Innovotech Inc. Announces CFO ChangesInnovotech Inc. has appointed Bernard Grobbelaar as CFO, effective immediately. Mr. Grobbelaar's new role is part of a greater realignment at Innovotech to strengthen the company's operations and improve its efficiency and capacity to scale. Mr. Grobbelaar will relinquish his Board of Directors seat, allowing him to maintain maximum independence. Mr. Grobbelaar is a Chartered Professional Accountant and provides services through his professional services firm, Oikonomos. The appointment of Mr. Grobbelaar completes a planned transition with Alan Savage concurrently resigning from his role as Innovotech CFO which the Board of Directors has accepted.Reported Earnings • Dec 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: CA$174.8k (down 49% from 3Q 2022). Net loss: CA$117.5k (down 382% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.Board Change • Sep 15Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Karen Farkas was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Aug 27Innovotech Inc. (TSXV:IOT) acquired 60% stake in Nou Life Sciences Inc..Innovotech Inc. (TSXV:IOT) entered into an agreement to acquire 60% stake in Nou Life Sciences Inc. on August 18, 2020. The transaction is in return for completing an investment of CAD 0.1 million in development expenses in Nou Life’s patented skin treatment technology. The transaction allows Innovotech to take up to two years to evaluate the technology, which rests on the linking of alpha lipoic acid and L-carnitine. David Tam is a common director of both the Company and Nou Life. As of January 19, 2021, TSX Venture Exchange approved the transaction.Innovotech Inc. (TSXV:IOT) completed the acquisition of 60% stake in Nou Life Sciences Inc. on August 25, 2023.Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: CA$411.0k (up 58% from 2Q 2022). Net income: CA$72.9k (up CA$135.4k from 2Q 2022). Profit margin: 18% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year whereas the company’s share price has fallen by 31% per year.お知らせ • Aug 08Innovotech Inc., Annual General Meeting, Oct 10, 2023Innovotech Inc., Annual General Meeting, Oct 10, 2023.Board Change • Jul 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 28Full year 2022 earnings released: CA$0.004 loss per share (vs CA$0.009 profit in FY 2021)Full year 2022 results: CA$0.004 loss per share (down from CA$0.009 profit in FY 2021). Revenue: CA$1.13m (down 24% from FY 2021). Net loss: CA$136.5k (down 137% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Board Change • Apr 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CA$340.5k (up 44% from 3Q 2021). Net income: CA$41.7k (up CA$63.2k from 3Q 2021). Profit margin: 12% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 28Innovotech Inc. Announces Retirement of Gerard Tertzakian as DirectorInnovotech Inc. announced that Dr. Gerard Tertzakian has retired from the Board after 20 years as a Director. Gerry was a Founder, former President and CEO, of Innovotech.分析記事 • Oct 12Estimating The Intrinsic Value Of Innovotech Inc. (CVE:IOT)Does the October share price for Innovotech Inc. ( CVE:IOT ) reflect what it's really worth? Today, we will estimate...Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 profit in 2Q 2021)Second quarter 2022 results: CA$0.002 loss per share (down from CA$0.004 profit in 2Q 2021). Revenue: CA$259.6k (down 46% from 2Q 2021). Net loss: CA$62.5k (down 138% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 06Innovotech Inc., Annual General Meeting, Oct 11, 2022Innovotech Inc., Annual General Meeting, Oct 11, 2022.Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 02Full year 2021 earnings released: EPS: CA$0.009 (vs CA$0.003 in FY 2020)Full year 2021 results: EPS: CA$0.009 (up from CA$0.003 in FY 2020). Revenue: CA$1.48m (up 24% from FY 2020). Net income: CA$367.1k (up 245% from FY 2020). Profit margin: 25% (up from 8.9% in FY 2020). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CA$480.2k (up 44% from 2Q 2020). Net income: CA$163.7k (up 34% from 2Q 2020). Profit margin: 34% (down from 37% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.Reported Earnings • May 27First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CA$308.6k (up 144% from 1Q 2020). Net income: CA$22.2k (up CA$137.5k from 1Q 2020). Profit margin: 7.2% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 24Full year 2020 earnings released: EPS CA$0.003 (vs CA$0.001 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$1.19m (up 21% from FY 2019). Net income: CA$106.3k (up CA$155.1k from FY 2019). Profit margin: 8.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 118 percentage points per year, which is a significant difference in performance.分析記事 • Mar 02Would Financials Be Able To Push Innovotech Inc.'s (CVE:IOT) Stock Prices Higher In The Near Future?Looking at Innovotech's (CVE:IOT) mostly flat share price movement over the past week, it is easy to think that there’s...Is New 90 Day High Low • Jan 12New 90-day high: CA$0.25The company is up 14% from its price of CA$0.22 on 08 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 13% over the same period.分析記事 • Jan 08Should You Take Comfort From Insider Transactions At Innovotech Inc. (CVE:IOT)?We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...Reported Earnings • Nov 16Third quarter 2020 earnings released: EPS CA$0.003The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CA$351.5k (up 41% from 3Q 2019). Net income: CA$93.2k (up CA$78.0k from 3Q 2019). Profit margin: 27% (up from 6.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 107% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.お知らせ • Sep 03+ 1 more updateInnovotech Inc. announced that it expects to receive CAD 0.375 million in fundingInnovotech Inc. (TSXV:IOT) announced a private placement of up to 1,875,000 units at a price of CAD 0.20 per unit for gross proceeds of up to CAD 375,000 on August 24, 2020. Each unit consists of one common share and one half one common share purchase warrant. Each warrant entitles the holder to purchase one additional share at a price of CAD 0.25 for a period of three years following the date of closing, subject to accelerated expiry should the common shares trade on the TSX Venture Exchange is equal to or exceeds CAD 0.40 for 20 consecutive trading days, the company shall have the right to accelerate the expiry date of the warrants to the date that is 30 days after the company has elected to exercise the acceleration right. The transaction is subject to regulatory approval. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Innovotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:IOT - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202640-10N/A12/31/202550-10N/A9/30/20254000N/A6/30/20254000N/A3/31/20253000N/A12/31/20242000N/A9/30/20241000N/A6/30/20241000N/A3/31/20241000N/A12/31/20231000N/A9/30/20231000N/A6/30/20231000N/A3/31/20231000N/A12/31/20221000N/A9/30/20221000N/A6/30/20221000N/A3/31/20221000N/A12/31/20211000N/A9/30/20211000N/A6/30/20212000N/A3/31/20211000N/A12/31/20201000N/A9/30/20201000N/A6/30/20201000N/A3/31/20201000N/A12/31/201910N/A0N/A9/30/201910N/A0N/A6/30/201910N/A0N/A3/31/201910N/A0N/A12/31/201810N/A0N/A9/30/201810N/A0N/A6/30/201811N/A0N/A3/31/201811N/A0N/A12/31/201711N/A0N/A9/30/201711N/A0N/A6/30/201710N/A0N/A3/31/201710N/A0N/A12/31/201610N/A0N/A9/30/201610N/A0N/A6/30/201610N/A0N/A3/31/201610N/A0N/A12/31/201510N/A0N/A9/30/201510N/A0N/A6/30/201510N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IOTの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: IOTの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: IOTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: IOTの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: IOTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IOTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 19:44終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innovotech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: CA$648.1k (down 44% from 1Q 2025). Net loss: CA$399.6k (down CA$464.8k from profit in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Apr 07Innovotech Inc., Annual General Meeting, Jun 16, 2026Innovotech Inc., Annual General Meeting, Jun 16, 2026. Location: alberta, edmonton Canada
Reported Earnings • Apr 04Full year 2025 earnings releasedFull year 2025 results: Revenue: CA$4.53m (up 107% from FY 2024). Net income: CA$94.4k (down 58% from FY 2024). Profit margin: 2.1% (down from 10% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.8% per year over the past 5 years. High level of non-cash earnings (68% accrual ratio). Market cap is less than US$10m (CA$8.32m market cap, or US$6.06m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$4.5m revenue, or US$3.2m).
お知らせ • Feb 07Innovotech Inc. Announces Executive Changes, Effective February 1, 2026Innovotech Inc. announced the appointments of Jodi McDonald as Chief Operating Officer and Rod Szarka as Chief Commercial Officer (CCO) of the Company, each effective February 1, 2026. Ms. McDonald was previously President of Keystone Labs Inc. (Keystone), which was recently amalgamated with Innovotech Labs Corporation (Labs). Both Keystone and Labs were wholly owned subsidiaries of Innovotech Inc., and their amalgamation into a single entity as Innovotech Labs Corporation was previously announced on January 2, 2026, having been completed on January 1st, 2026. Ms. McDonald has led Keystone for more than 20 years, building and scaling a regulated laboratory business with a strong focus on quality, client service and team development. She holds a Bachelor of Science in Medical Laboratory Science from the University of Alberta. The company announced the appointment of Rod Szarka as Chief Commercial Officer. Mr. Szarka was previously Vice President of Marketing and Business Development at Keystone, where he was responsible for building client relationships and expanding service offerings. In his new role as CCO of Innovotech, Mr. Szarka will oversee revenue generation across the Company, including responsibility for business development, client relationships and the buildout of a dedicated sales and client service team for all Innovotech business lines.out of a dedicated sales and client service team for all Innovotech business lines. Rod has a strong track record of translating technical capabilities into clear value for clients, added Dr. Milne. His experience growing Keystones client base and his understanding of the needs of regulated life sciences companies make him the right leader to build out Innovotechs commercial engine. With Jodi focused on operations and Rod focused on growth, we are strengthening the leadership team needed to scale our life sciences business.
New Risk • Dec 04New major risk - Revenue and earnings growthEarnings have declined by 9.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.8% per year over the past 5 years. High level of non-cash earnings (68% accrual ratio). Market cap is less than US$10m (CA$10.5m market cap, or US$7.54m). Minor Risk Revenue is less than US$5m (CA$4.5m revenue, or US$3.2m).
お知らせ • Nov 21Innovotech Inc. announced that it has received CAD 0.2 million in fundingOn November 20, 2025, Innovotech Inc. closed the transaction. No finders' fees were paid with respect to the offering. The company announced that it has closed on the convertible debenture for an aggregate principal amount of CAD 200,000. The debenture and all accrued and unpaid interest shall mature on October 15, 2030, being 60 months from the date of issuance of the debenture. The principal amount of the debenture may, at the option of the debenture holder, be converted, in whole or in part, at any time before the maturity date into common shares of company at a price of CAD 0.25 per common share.
Recent Insider Transactions Derivative • Sep 28Independent Director exercised options to buy CA$118k worth of stock.On the 24th of September, Shong-Tak Tam exercised options to buy 589k shares at a strike price of around CA$0.17, costing a total of CA$100k. This transaction amounted to 22% of their direct individual holding at the time of the trade. Since December 2024, Shong-Tak's direct individual holding has increased from 1.85m shares to 2.72m. Company insiders have collectively bought CA$430k more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Aug 21Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.003 loss in 2Q 2024)Second quarter 2025 results: CA$0.005 loss per share (further deteriorated from CA$0.003 loss in 2Q 2024). Revenue: CA$984.3k (up 147% from 2Q 2024). Net loss: CA$239.5k (loss widened 109% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 09+ 1 more updateAn undisclosed buyer acquired an undisclosed stake in CanBiocin Inc. from Innovotech Inc. (TSXV:IOT) for CAD 0.55 million.An undisclosed buyer acquired an undisclosed stake in CanBiocin Inc. from Innovotech Inc. (TSXV:IOT) for CAD 0.55 million on July 1, 2025. As part of the consideration, Innovotech Inc. (TSX-V: IOT) has received approximately CAD 0.550562 million following the sale of its 0.12 million shares in CanBiocin. An undisclosed buyer completed the acquisition of an undisclosed stake in CanBiocin Inc. from Innovotech Inc. (TSXV:IOT) for CAD 0.55 million on July 1, 2025.
Recent Insider Transactions • May 19Independent Director recently bought CA$92k worth of stockOn the 14th of May, Shong-Tak Tam bought around 434k shares on-market at roughly CA$0.21 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$279k more in shares than they have sold in the last 12 months.
Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: CA$1.16m (up 269% from 1Q 2024). Net income: CA$65.2k (up CA$167.4k from 1Q 2024). Profit margin: 5.6% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
お知らせ • May 06Innovotech Inc., Annual General Meeting, Jul 08, 2025Innovotech Inc., Annual General Meeting, Jul 08, 2025.
Reported Earnings • Apr 16Full year 2024 earnings releasedFull year 2024 results: Revenue: CA$2.19m (up 86% from FY 2023). Net income: CA$224.7k (up CA$382.3k from FY 2023). Profit margin: 10% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 20Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: CA$436.1k (up 150% from 3Q 2023). Net loss: CA$21.3k (loss narrowed 82% from 3Q 2023).
New Risk • Nov 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m (CA$1.2m revenue, or US$878k). Market cap is less than US$10m (CA$6.13m market cap, or US$4.38m). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding).
お知らせ • Nov 06+ 1 more updateInnovotech Inc. (TSXV:IOT) completed the acquisition of Keystone Labs Inc.Innovotech Inc. (TSXV:IOT) signed a letter of intent to acquire Keystone Labs Inc. for CAD 0.52 million on September 10, 2024. As part of consideration, CAD 0.3 million is paid towards common equity of Keystone Labs Inc. The consideration for the acquisition of the Keystone equity will be in an amount of up to $600,000 by the issuance to the Keystone shareholders the equivalent of CAD 300,000 of Innovotech shares from treasury at the price of CAD 0.13 per common share. These acquisition Shares will be subject to an escrow agreement whereby the Acquisition Shares shall be released over a two-year period, which is designed to retain Ms. McDonald in her leadership capacity. Additionally, the Company will issue a performance-based cash incentive plan valued at up to a further CAD 300,000 over a three-year period contingent on achieving revenue growth and positive net income targets. The LOI will be followed by a definitive agreement which will be subject to customary conditions, due diligence and representations, warranties and covenants. As of October 21, 2024, Innovotech Inc. signed a definitive purchase agreement to acquire Keystone Labs Inc. for CAD 0.51 million. Innovotech will acquire 100% of Keystone’s shares on a debt-free basis for up to CAD 516,698. This includes issuing CAD 216,698 in Innovotech shares at CAD 0.13 per common share. A performance-based cash incentive plan of up to CAD 300,000 is also offered, contingent on revenue growth and positive net income over three years. On October 30, 2024 conditional acceptance by the TSX Venture Exchange. Innovotech anticipated closing date in October of 2024. The closing date is expected to be in the latter part of November 2024, subject to the acceptance of the TSX Venture Exchange (TSXV). Innovotech Inc. (TSXV:IOT) completed the acquisition of Keystone Labs Inc. on November 5, 2024.
お知らせ • Sep 12+ 1 more updateInnovotech Inc. (TSXV:IOT) signed a letter of intent to acquire Keystone Labs Inc. for CAD 0.9 million.Innovotech Inc. (TSXV:IOT) signed a letter of intent to acquire Keystone Labs Inc. for CAD 0.9 million on September 10, 2024. A cash consideration of CAD 0.3 million will be paid by Innovotech Inc. As part of consideration, CAD 0.3 million is paid towards common equity of Keystone Labs Inc. Innovotech anticipated closing date in October of 2024. The consideration for the acquisition of the Keystone equity will be in an amount of up to $600,000 by the issuance to the Keystone shareholders the equivalent of CAD 300,000 of Innovotech shares from treasury at the price of CAD 0.13 per common share. These Acquisition Shares will be subject to an escrow agreement whereby the Acquisition Shares shall be released over a two-year period, which is designed to retain Ms. McDonald in her leadership capacity. Additionally, the Company will issue a performance-based cash incentive plan valued at up to a further CAD 300,000 over a three-year period contingent on achieving revenue growth and positive net income targets. The Company is also pleased to announce a non-brokered private placement of up to CAD 1,000,000. The LOI will be followed by a definitive agreement which will be subject to customary conditions, due diligence and representations, warranties and covenants. The Company intends to use CAD 300,000 to clear the existing shareholder loan balances at Keystone and a further CAD 100,000 for equipment purchases as required in the short to medium term to augment Keystone’s existing laboratory equipment. The balance of the proceeds from the private placement will be used for unallocated working capital and for conducting further business development of the combined business operations.
Reported Earnings • Aug 22Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: CA$398.6k (down 3.0% from 2Q 2023). Net loss: CA$114.8k (down 258% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 115 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions Derivative • Aug 18President exercised options to buy CA$5.6k worth of stock.On the 15th of August, Craig Milne exercised options to buy 40k shares at a strike price of around CA$3,200, costing a total of CA$128m. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2023, Craig's direct individual holding has increased from 160.00k shares to 294.00k. Company insiders have collectively bought CA$128m more than they sold, via options and on-market transactions, in the last 12 months.
お知らせ • May 16Innovotech Inc., Annual General Meeting, Jul 16, 2024Innovotech Inc., Annual General Meeting, Jul 16, 2024.
Reported Earnings • Apr 25Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.004 loss in FY 2022)Full year 2023 results: CA$0.004 loss per share (in line with FY 2022). Revenue: CA$1.18m (up 5.0% from FY 2022). Net loss: CA$157.6k (loss widened 15% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • Dec 13Innovotech Inc. Announces CFO ChangesInnovotech Inc. has appointed Bernard Grobbelaar as CFO, effective immediately. Mr. Grobbelaar's new role is part of a greater realignment at Innovotech to strengthen the company's operations and improve its efficiency and capacity to scale. Mr. Grobbelaar will relinquish his Board of Directors seat, allowing him to maintain maximum independence. Mr. Grobbelaar is a Chartered Professional Accountant and provides services through his professional services firm, Oikonomos. The appointment of Mr. Grobbelaar completes a planned transition with Alan Savage concurrently resigning from his role as Innovotech CFO which the Board of Directors has accepted.
Reported Earnings • Dec 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: CA$174.8k (down 49% from 3Q 2022). Net loss: CA$117.5k (down 382% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
Board Change • Sep 15Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Karen Farkas was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Aug 27Innovotech Inc. (TSXV:IOT) acquired 60% stake in Nou Life Sciences Inc..Innovotech Inc. (TSXV:IOT) entered into an agreement to acquire 60% stake in Nou Life Sciences Inc. on August 18, 2020. The transaction is in return for completing an investment of CAD 0.1 million in development expenses in Nou Life’s patented skin treatment technology. The transaction allows Innovotech to take up to two years to evaluate the technology, which rests on the linking of alpha lipoic acid and L-carnitine. David Tam is a common director of both the Company and Nou Life. As of January 19, 2021, TSX Venture Exchange approved the transaction.Innovotech Inc. (TSXV:IOT) completed the acquisition of 60% stake in Nou Life Sciences Inc. on August 25, 2023.
Reported Earnings • Aug 16Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: CA$411.0k (up 58% from 2Q 2022). Net income: CA$72.9k (up CA$135.4k from 2Q 2022). Profit margin: 18% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year whereas the company’s share price has fallen by 31% per year.
お知らせ • Aug 08Innovotech Inc., Annual General Meeting, Oct 10, 2023Innovotech Inc., Annual General Meeting, Oct 10, 2023.
Board Change • Jul 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 28Full year 2022 earnings released: CA$0.004 loss per share (vs CA$0.009 profit in FY 2021)Full year 2022 results: CA$0.004 loss per share (down from CA$0.009 profit in FY 2021). Revenue: CA$1.13m (down 24% from FY 2021). Net loss: CA$136.5k (down 137% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Board Change • Apr 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CA$340.5k (up 44% from 3Q 2021). Net income: CA$41.7k (up CA$63.2k from 3Q 2021). Profit margin: 12% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 28Innovotech Inc. Announces Retirement of Gerard Tertzakian as DirectorInnovotech Inc. announced that Dr. Gerard Tertzakian has retired from the Board after 20 years as a Director. Gerry was a Founder, former President and CEO, of Innovotech.
分析記事 • Oct 12Estimating The Intrinsic Value Of Innovotech Inc. (CVE:IOT)Does the October share price for Innovotech Inc. ( CVE:IOT ) reflect what it's really worth? Today, we will estimate...
Reported Earnings • Aug 18Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 profit in 2Q 2021)Second quarter 2022 results: CA$0.002 loss per share (down from CA$0.004 profit in 2Q 2021). Revenue: CA$259.6k (down 46% from 2Q 2021). Net loss: CA$62.5k (down 138% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 06Innovotech Inc., Annual General Meeting, Oct 11, 2022Innovotech Inc., Annual General Meeting, Oct 11, 2022.
Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 02Full year 2021 earnings released: EPS: CA$0.009 (vs CA$0.003 in FY 2020)Full year 2021 results: EPS: CA$0.009 (up from CA$0.003 in FY 2020). Revenue: CA$1.48m (up 24% from FY 2020). Net income: CA$367.1k (up 245% from FY 2020). Profit margin: 25% (up from 8.9% in FY 2020). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CA$480.2k (up 44% from 2Q 2020). Net income: CA$163.7k (up 34% from 2Q 2020). Profit margin: 34% (down from 37% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.
Reported Earnings • May 27First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CA$308.6k (up 144% from 1Q 2020). Net income: CA$22.2k (up CA$137.5k from 1Q 2020). Profit margin: 7.2% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 24Full year 2020 earnings released: EPS CA$0.003 (vs CA$0.001 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$1.19m (up 21% from FY 2019). Net income: CA$106.3k (up CA$155.1k from FY 2019). Profit margin: 8.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 118 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 02Would Financials Be Able To Push Innovotech Inc.'s (CVE:IOT) Stock Prices Higher In The Near Future?Looking at Innovotech's (CVE:IOT) mostly flat share price movement over the past week, it is easy to think that there’s...
Is New 90 Day High Low • Jan 12New 90-day high: CA$0.25The company is up 14% from its price of CA$0.22 on 08 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 13% over the same period.
分析記事 • Jan 08Should You Take Comfort From Insider Transactions At Innovotech Inc. (CVE:IOT)?We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Reported Earnings • Nov 16Third quarter 2020 earnings released: EPS CA$0.003The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CA$351.5k (up 41% from 3Q 2019). Net income: CA$93.2k (up CA$78.0k from 3Q 2019). Profit margin: 27% (up from 6.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 107% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.
お知らせ • Sep 03+ 1 more updateInnovotech Inc. announced that it expects to receive CAD 0.375 million in fundingInnovotech Inc. (TSXV:IOT) announced a private placement of up to 1,875,000 units at a price of CAD 0.20 per unit for gross proceeds of up to CAD 375,000 on August 24, 2020. Each unit consists of one common share and one half one common share purchase warrant. Each warrant entitles the holder to purchase one additional share at a price of CAD 0.25 for a period of three years following the date of closing, subject to accelerated expiry should the common shares trade on the TSX Venture Exchange is equal to or exceeds CAD 0.40 for 20 consecutive trading days, the company shall have the right to accelerate the expiry date of the warrants to the date that is 30 days after the company has elected to exercise the acceleration right. The transaction is subject to regulatory approval.